Eloralintide for Obstructive Sleep Apnea in Adults With Obesity or Overweight
Tests eloralintide in adults with obstructive sleep apnea and excess weight.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Key facts
- Where
- Guadalajara, Lleida, Logroño, Madrid, Málaga, and Seville, SpainSee the 9 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate-to-severe obstructive sleep apnea who also have obesity or overweight. It tests once-weekly eloralintide against placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Moderate-to-severe obstructive sleep apnea (AHI ≥ 15 on a sleep study at screening) with a BMI ≥27 kg/m2
- Earlier treatment
- At least one self-reported unsuccessful dietary effort to lose weight. One part of the study is for people who cannot or will not use PAP therapy. The other part is for people who have used PAP for at least 3 months and plan to continue.
Main reasons for not taking part
- Any type of diabetes
- Past or planned surgery or device treatment for obesity (some exceptions apply)
- Past or planned surgery for sleep apnea or major ear, nose or throat surgery that may still affect breathing
- Heart attack, stroke, heart artery procedure, unstable angina or hospital stay for heart failure within 90 days before screening
- Weight-loss medicines or remedies within 90 days before screening
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario de GuadalajaraGuadalajara, SpainTaking people
- Hospital Universitari de Santa MariaLleida, SpainTaking people
- Hospital San PedroLogroño, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Instituto de Investigaciones del SuenoMadrid, SpainTaking people
- Hospital Universitario Virgen de la VictoriaMálaga, SpainTaking people
- Hospital Quiron Infanta LuisaSeville, SpainTaking people
- Hospital Universitario Virgen del RocioSeville, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07369011EU 2025-523769-11-00
- Record updated
- 4 November 2026
- Original description
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.
Inclusion: Confirmed history of moderate-to-severe OSA; Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening; Have a BMI ≥27 kg/m2 at screening; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight; For YSA1 Participants:; Are unable or unwilling to use PAP therapy; For YSA2 Participants:; Have been on PAP therapy for at least three consecutive months prior to screening and plan to continue PAP therapy during the study.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening; Have had within 90 days prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.